Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP 78 Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.66 (Fairly Valued). The stock has 3 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Biohit Oyj ranks better than 85.98% on this metric.
Biohit Oyj's Enterprise Value for the quarter that ended in Jun. 2026 was €38.34 Mil.
Biohit Oyj's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €3.30 Mil. Biohit Oyj's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 0.00%.
The historical rank and industry rank for Biohit Oyj's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LTS:0DRP'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14.67 Med: -3.63 Max: 18.01
Current: 8.44
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Biohit Oyj was 18.01%. The lowest was -14.67%. And the median was -3.63%.
LTS:0DRP's Earnings Yield (Joel Greenblatt) % is ranked better than 85.98% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 0.86
vs LTS:0DRP: 8.44
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biohit Oyj's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Biohit Oyj Earnings Yield (Joel Greenblatt) % Related Terms
Biohit Oyj Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biohit Oyj's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Biohit Oyjs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Biohit Oyj (LTS:0DRP) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #119 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is Biohit Oyj's Earnings Yield (Joel Greenblatt) % too high?
Biohit Oyj's current Earnings Yield (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Biohit Oyj ranks #119 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #119 out of 849 companies for Earnings Yield (Joel Greenblatt) %. This places Biohit Oyj in the top 14% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 0.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.86, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.66, compared to a current price of €2.67 — trading 0.4% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.67 is trading 0.4% above its estimated GF Value™ of €2.66.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
Earnings Yield (Joel Greenblatt) %: 0.00%
GF Value™: €2.66 vs. price of €2.67 (0.4% above fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
